Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Assertifarma's pivotal US team, with crucial experience on a competitor's drug, was found by chance. BGV's founder was pitched by them at a conference but flipped the script and recruited them for his own project, proving the power of opportunistic networking and recognizing expertise on the fly.

Related Insights

Cereno's CEO leveraged a consultancy market downturn to his advantage. Having worked with a firm on strategy and communications, he seized the opportunity when it closed down, hiring four key people he already knew and trusted, instantly building out his internal team with proven talent.

NervGen's CEO, Adam Rogers, was introduced to the company when his son, interning for board advisor Rich Macary, was assigned to research NervGen. This highlights the unexpected and informal networks through which key executive talent can be sourced, originating from a simple internship assignment.

As a newcomer to biotech, Celcuity's CEO used search firms to recruit his initial senior leadership team. Those leaders then used their extensive personal networks to hire the entire 90-person sales force through internal referrals, ensuring a strong cultural fit and high-caliber team.

The highly successful company Assertifarma was developed entirely in "stealth mode." This strategy allowed them to advance their drug and generate compelling clinical data without alerting the competitive landscape, maximizing impact by revealing results and the company's existence during M&A talks.

Cereno's CEO reconnected with a prominent cardiologist he'd worked with 20 years earlier. This long-dormant relationship was pivotal; the expert agreed to chair the Scientific Advisory Board and then recruited other leading physicians, instantly giving the company top-tier scientific validation.

BGV's massive success, Assertifarma, originated from a Merck reorganization. The founding team, who were being let go, identified a shelved drug intended for inflammation and repurposed it for leukemia, negotiating the license amidst the corporate shuffle. This highlights the hidden opportunities within large pharma portfolios.

To find a Chief Scientific Officer with a rare combination of skills, EARLI's CEO used LinkedIn search. He combined terms like "gene therapy," "venture," and "FDA experience" to narrow the global candidate pool to about 25 people, proving precise digital sourcing can outperform traditional networking for highly specialized roles.

Critical expertise doesn't always come from industry conferences or formal channels. The CEO of Versatope found a key CMC consultant at a Boy Scout event. This demonstrates the value of discussing your work in everyday settings, as crucial team members can be found in the most unexpected places.

After their lead program failed, Palisade Bio was in the process of hiring a Chief Medical Officer. The candidate, Mitch Jones, proposed acquiring an asset he had been following. This serendipitous hire led to a complete company pivot, demonstrating how strategic talent acquisition can redefine a company's trajectory.

Most top investors bet on the team as much as the science. A first-time founder must recruit experienced advisors, board members, and executives who have the network, profile, and track record that venture investors recognize and value to secure large rounds.